Home›Companies›Biotech & Pharma›EndLyz

Endlyz Therapeutics, Inc.

Develops potential medicines for people with Parkinson’s disease and other dementias.

Updated Nov 10, 2026·Latest SEC filing May 7, 2026·Suggest an edit

About EndLyz

EndLyz is a private company based in Boston, Massachusetts. It has reported $20,500,395 raised in two offerings on Form D since July 2021. Its chief executive is Joanna Wolak.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 31, 2026May 7, 2026$17,250,395of $19.6M target7$2.4MEquityRule 506(b)Form D ↗
Jul 16, 2021Jul 29, 2021$3,250,000of $6.5M target6$541KEquityRule 506(b)Form D ↗
Total, two offerings$20,500,395

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on EndLyz's Form D filed May 7, 2026.

JF
Justian Fox
Director
Donmienne Leung
Donmienne Leung
Director, AbbVie Ventures
Laurence Barker
Laurence Barker
Partner, SV Health Investors and director
Timothy Edwards
Timothy Edwards
Chairperson, Independent
Joanna Wolak
Joanna Wolak
CEO and Co-founder, director

Earlier filings also listed Zaven Kaprielian (president and director, last listed Jul 2021), Jonathan Behr (director, last listed Jul 2021), John Gustofson (director, last listed Jul 2021) and Damian Crowther (director, last listed Jul 2021).

Sources

  1. SECEndlyz Therapeutics, Inc. filing history